Literature DB >> 27349790

Novel high/low solubility classification methods for new molecular entities.

Rutwij A Dave1, Marilyn E Morris2.   

Abstract

This research describes a rapid solubility classification approach that could be used in the discovery and development of new molecular entities. Compounds (N=635) were divided into two groups based on information available in the literature: high solubility (BDDCS/BCS 1/3) and low solubility (BDDCS/BCS 2/4). We established decision rules for determining solubility classes using measured log solubility in molar units (MLogSM) or measured solubility (MSol) in mg/ml units. ROC curve analysis was applied to determine statistically significant threshold values of MSol and MLogSM. Results indicated that NMEs with MLogSM>-3.05 or MSol>0.30mg/mL will have ≥85% probability of being highly soluble and new molecular entities with MLogSM≤-3.05 or MSol≤0.30mg/mL will have ≥85% probability of being poorly soluble. When comparing solubility classification using the threshold values of MLogSM or MSol with BDDCS, we were able to correctly classify 85% of compounds. We also evaluated solubility classification of an independent set of 108 orally administered drugs using MSol (0.3mg/mL) and our method correctly classified 81% and 95% of compounds into high and low solubility classes, respectively. The high/low solubility classification using MLogSM or MSol is novel and independent of traditionally used dose number criteria.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Analytical chemistry; Computational ADME; Computer aided drug design; High throughput technologies; In silico modeling; ROC curve analysis; Solubility

Mesh:

Substances:

Year:  2016        PMID: 27349790      PMCID: PMC5003747          DOI: 10.1016/j.ijpharm.2016.06.060

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  26 in total

Review 1.  Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group.

Authors:  C Vitali; S Bombardieri; R Jonsson; H M Moutsopoulos; E L Alexander; S E Carsons; T E Daniels; P C Fox; R I Fox; S S Kassan; S R Pillemer; N Talal; M H Weisman
Journal:  Ann Rheum Dis       Date:  2002-06       Impact factor: 19.103

2.  Receiver operating characteristic curves and their use in radiology.

Authors:  Nancy A Obuchowski
Journal:  Radiology       Date:  2003-10       Impact factor: 11.105

3.  BDDCS applied to over 900 drugs.

Authors:  Leslie Z Benet; Fabio Broccatelli; Tudor I Oprea
Journal:  AAPS J       Date:  2011-08-05       Impact factor: 4.009

4.  In silico prediction of aqueous solubility.

Authors:  John C Dearden
Journal:  Expert Opin Drug Discov       Date:  2006-06       Impact factor: 6.098

5.  The meaning and use of the area under a receiver operating characteristic (ROC) curve.

Authors:  J A Hanley; B J McNeil
Journal:  Radiology       Date:  1982-04       Impact factor: 11.105

6.  pH-Dependent solubility and permeability criteria for provisional biopharmaceutics classification (BCS and BDDCS) in early drug discovery.

Authors:  Manthena V Varma; Iain Gardner; Stefanus J Steyn; Paul Nkansah; Charles J Rotter; Carrie Whitney-Pickett; Hui Zhang; Li Di; Michael Cram; Katherine S Fenner; Ayman F El-Kattan
Journal:  Mol Pharm       Date:  2012-04-26       Impact factor: 4.939

7.  Prediction of biliary excretion in rats and humans using molecular weight and quantitative structure-pharmacokinetic relationships.

Authors:  Xinning Yang; Yash A Gandhi; David B Duignan; Marilyn E Morris
Journal:  AAPS J       Date:  2009-07-11       Impact factor: 4.009

8.  Purely in silico BCS classification: science based quality standards for the world's drugs.

Authors:  Arik Dahan; Omri Wolk; Young Hoon Kim; Chandrasekharan Ramachandran; Gordon M Crippen; Toshihide Takagi; Marival Bermejo; Gordon L Amidon
Journal:  Mol Pharm       Date:  2013-10-23       Impact factor: 4.939

9.  A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability.

Authors:  G L Amidon; H Lennernäs; V P Shah; J R Crison
Journal:  Pharm Res       Date:  1995-03       Impact factor: 4.200

10.  Statistics review 13: receiver operating characteristic curves.

Authors:  Viv Bewick; Liz Cheek; Jonathan Ball
Journal:  Crit Care       Date:  2004-11-04       Impact factor: 9.097

View more
  8 in total

1.  Evaluation of DILI Predictive Hypotheses in Early Drug Development.

Authors:  Rosa Chan; Leslie Z Benet
Journal:  Chem Res Toxicol       Date:  2017-03-15       Impact factor: 3.739

2.  Measures of BSEP Inhibition In Vitro Are Not Useful Predictors of DILI.

Authors:  Rosa Chan; Leslie Z Benet
Journal:  Toxicol Sci       Date:  2018-04-01       Impact factor: 4.849

3.  Evaluation of the Relevance of DILI Predictive Hypotheses in Early Drug Development: Review of In Vitro Methodologies vs BDDCS Classification.

Authors:  Rosa Chan; Leslie Z Benet
Journal:  Toxicol Res (Camb)       Date:  2018-04-18       Impact factor: 3.524

4.  Population Pharmacokinetic Analyses and Model Validation of Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease.

Authors:  Shankar Lanke; Susan E Shoaf
Journal:  J Clin Pharmacol       Date:  2019-01-07       Impact factor: 3.126

5.  Hypomethylating Agent Azacitidine Is Effective in Treating Brain Metastasis Triple-Negative Breast Cancer Through Regulation of DNA Methylation of Keratin 18 Gene.

Authors:  Christopher Butler; Samuel Sprowls; Gabor Szalai; Tasneem Arsiwala; Pushkar Saralkar; Benjamin Straight; Shea Hatcher; Evan Tyree; Michael Yost; William J Kohler; Benjamin Wolff; Emily Putnam; Paul Lockman; Tuoen Liu
Journal:  Transl Oncol       Date:  2020-05-11       Impact factor: 4.243

6.  A comprehensive WGS-based pipeline for the identification of new candidate genes in inherited retinal dystrophies.

Authors:  María González-Del Pozo; Elena Fernández-Suárez; Nereida Bravo-Gil; Cristina Méndez-Vidal; Marta Martín-Sánchez; Enrique Rodríguez-de la Rúa; Manuel Ramos-Jiménez; María José Morillo-Sánchez; Salud Borrego; Guillermo Antiñolo
Journal:  NPJ Genom Med       Date:  2022-03-04       Impact factor: 8.617

Review 7.  State of the Art and Uses for the Biopharmaceutics Drug Disposition Classification System (BDDCS): New Additions, Revisions, and Citation References.

Authors:  Giovanni Bocci; Tudor I Oprea; Leslie Z Benet
Journal:  AAPS J       Date:  2022-02-23       Impact factor: 3.603

8.  Thermodynamic modelling of solubility and preferential solvation for ribavirin (II) in co-solvent mixtures of (methanol, n-propanol, acetonitrile or 1,4-dioxane) + water.

Authors:  Xinbao Li; Yang Cong; Wentian Li; Pengyao Yan; Hongkun Zhao
Journal:  J Chem Thermodyn       Date:  2017-07-24       Impact factor: 3.178

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.